Comparative Effectiveness of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications vs. Usual Care
Relative Hematoma Expansion Is Reduced After rFVIIa Use in Spontaneous Intracranial Hemorrhage
Meta-analysis demonstrated significant reductions in the relative hematoma expansion for patients in the rFVIIa group when compared to the usual care group at all dosing levels. While the large Mayer 2005 study reported a significant dose-response effect of reduced hematoma growth with higher doses of rFVIIa, statistical tests for differences between dosing levels in our meta-analyses found no significant dose effect.
- Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005;352:777-85.
- Yank V, Tuohy CV, Logan AC, et al. Comparative Effectiveness of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications vs. Usual Care, Comparative Effectiveness Review 21 (Prepared by Stanford–UCSF Evidence-based Practice Center under Contract No. 290-02-0017). Rockville, MD: Agency for Healthcare Research and Quality; May 2010. AHRQ Publication No. 10-EHC030-EF.
Your slide tray is being processed.